TASIGNA has a manageable safety profile in newly diagnosed patients, as seen in ENESTnd1,2

These ENESTnd 60-month follow-up data reflect exposure to TASIGNA in 279 patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated with 300 mg of nilotinib twice daily.

Hematologic AEs occurring on TKI therapy reported in ENESTnd1,2

Hematologic AEs occurring on TKI therapy reported in ENESTnd

Nonhematologic AEs occurring on TKI therapy reported in ENESTnd1,2

Nonhematologic AEs occurring on TKI therapy reported in ENESTnd

Low rates of discontinuation seen with TASIGNA in ENESTnd1

  • TASIGNA has manageable tolerability in patients with Ph+ CML-CP1
  • In ENESTnd, more patients on imatinib discontinued therapy by 5 years due to AEs vs TASIGNA (13.4% vs 12.1%).2 Median time on treatment was 60.5 months (range 0.1 - 70.8 months)1

AE categories are based on those listed in the ELN recommendations for management and avoidance of AEs of treatment in CML (Steegmann JL et al. Leukemia. 2016;30(8):1648-1671).3

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BID, twice a day; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase; NR, not reported.

  1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; May 2017.
  2. Hochhaus A, et al. Leukemia. 2016;30:1044-1054.
  3. Steegmann JL et al. Leukemia. 2016;30(8):1648-1671.